FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386326323> ?p ?o ?g. }

• W4386326323 abstract "For patients with extensive-stage small cell lung cancer (ES-SCLC), serplulimab plus chemotherapy is beneficial as the first-line treatment. It is uncertain whether serplulimab plus chemotherapy will be more cost-effective. The aim of this study was to evaluate from the perspective of the Chinese healthcare system to assess the cost-effectiveness of serplulimab plus chemotherapy for patients with ES-SCLC.This study employed a partitioned survival model. Patients in the model were selected from ASTRUM-005 for their clinical characteristics and outcomes. In order to assess the robustness of the model, we conducted deterministic one-way sensitivity analyzes as well as probabilistic sensitivity analyzes. Subgroup analyzes were also conducted. Costs, quality-adjusted life-years (QALYs), life-years, incremental cost-effectiveness ratio (ICER), incremental net health benefits (INHB), and incremental net monetary benefits (INMB) were analyzed.Based on the base-case analysis, serplulimab plus chemotherapy contributed to an increase in 0.826 life-years and 0.436 QALYs; an incremental cost of $52,331, yielded ICER of $120,149/QALY. Based on the willingness to pay (WTP) threshold of $37,669/QALY and $86,569/QALY, the INHB was -0.954 QALYs and - 0.169 QALYs and the INMB was -$35,924 and -$14,626, respectively. Based on the probabilistic sensitivity analysis results, serplulimab plus chemotherapy was unlikely to be cost-effective at a WTP threshold of $37,669/QALY and $86,569/QALY. One-way sensitivity analysis indicated that cost of serplulimab and body weight had the greatest impact on the model. Serplulimab plus chemotherapy could be cost-effective at a WTP threshold of $86,569/QALY when the cost of serplulimab was less than $5.24/mg or when the weight of the patient was less than 40.96 kg. Regardless of the WTP threshold at $37,669/QALY or $86,569. Serplulimab plus chemotherapy was not cost-effective in all subgroups.Serplulimab plus chemotherapy was not cost-effective, despite having a prior clinical benefical and a relative safety profile compared with chemotherapy. With the reduction in the price of serplulimab, ES-SCLC patients treated with serplulimab plus chemotherapy may be able to achieve a favorable cost-effectiveness rate." @default.
• W4386326323 created "2023-09-01" @default.
• W4386326323 creator A5010236351 @default.
• W4386326323 creator A5038805449 @default.
• W4386326323 creator A5043094856 @default.
• W4386326323 creator A5065722429 @default.
• W4386326323 date "2023-08-31" @default.
• W4386326323 modified "2023-09-27" @default.
• W4386326323 title "Cost-effectiveness analysis of first-line serplulimab combined with chemotherapy for extensive-stage small cell lung cancer" @default.
• W4386326323 cites W1547463098 @default.
• W4386326323 cites W1975731597 @default.
• W4386326323 cites W1977373411 @default.
• W4386326323 cites W1982967337 @default.
• W4386326323 cites W1995517770 @default.
• W4386326323 cites W2010913334 @default.
• W4386326323 cites W2015907357 @default.
• W4386326323 cites W2132836850 @default.
• W4386326323 cites W2177197858 @default.
• W4386326323 cites W2296800272 @default.
• W4386326323 cites W2516994167 @default.
• W4386326323 cites W2744137087 @default.
• W4386326323 cites W2765782352 @default.
• W4386326323 cites W2798010797 @default.
• W4386326323 cites W2893960509 @default.
• W4386326323 cites W2900705321 @default.
• W4386326323 cites W2977392388 @default.
• W4386326323 cites W2991462158 @default.
• W4386326323 cites W3030178583 @default.
• W4386326323 cites W3046449570 @default.
• W4386326323 cites W3093338574 @default.
• W4386326323 cites W3121328438 @default.
• W4386326323 cites W3123873764 @default.
• W4386326323 cites W3128646645 @default.
• W4386326323 cites W3130803591 @default.
• W4386326323 cites W3212416264 @default.
• W4386326323 cites W4200232423 @default.
• W4386326323 cites W4200316162 @default.
• W4386326323 cites W4205155893 @default.
• W4386326323 cites W4205387561 @default.
• W4386326323 cites W4206121490 @default.
• W4386326323 cites W4206195485 @default.
• W4386326323 cites W4225985415 @default.
• W4386326323 cites W4286222575 @default.
• W4386326323 cites W4288085754 @default.
• W4386326323 cites W4296028938 @default.
• W4386326323 cites W4297225412 @default.
• W4386326323 cites W4297251744 @default.
• W4386326323 cites W4307349589 @default.
• W4386326323 cites W4308551217 @default.
• W4386326323 cites W4313585194 @default.
• W4386326323 doi "https://doi.org/10.3389/fpubh.2023.1156427" @default.
• W4386326323 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37727602" @default.
• W4386326323 hasPublicationYear "2023" @default.
• W4386326323 type Work @default.
• W4386326323 citedByCount "0" @default.
• W4386326323 crossrefType "journal-article" @default.
• W4386326323 hasAuthorship W4386326323A5010236351 @default.
• W4386326323 hasAuthorship W4386326323A5038805449 @default.
• W4386326323 hasAuthorship W4386326323A5043094856 @default.
• W4386326323 hasAuthorship W4386326323A5065722429 @default.
• W4386326323 hasBestOaLocation W43863263231 @default.
• W4386326323 hasConcept C112930515 @default.
• W4386326323 hasConcept C126322002 @default.
• W4386326323 hasConcept C127454912 @default.
• W4386326323 hasConcept C143998085 @default.
• W4386326323 hasConcept C162324750 @default.
• W4386326323 hasConcept C175444787 @default.
• W4386326323 hasConcept C18903297 @default.
• W4386326323 hasConcept C2776256026 @default.
• W4386326323 hasConcept C2776694085 @default.
• W4386326323 hasConcept C2777364431 @default.
• W4386326323 hasConcept C2779900020 @default.
• W4386326323 hasConcept C3019080777 @default.
• W4386326323 hasConcept C515549039 @default.
• W4386326323 hasConcept C64332521 @default.
• W4386326323 hasConcept C71924100 @default.
• W4386326323 hasConcept C86803240 @default.
• W4386326323 hasConceptScore W4386326323C112930515 @default.
• W4386326323 hasConceptScore W4386326323C126322002 @default.
• W4386326323 hasConceptScore W4386326323C127454912 @default.
• W4386326323 hasConceptScore W4386326323C143998085 @default.
• W4386326323 hasConceptScore W4386326323C162324750 @default.
• W4386326323 hasConceptScore W4386326323C175444787 @default.
• W4386326323 hasConceptScore W4386326323C18903297 @default.
• W4386326323 hasConceptScore W4386326323C2776256026 @default.
• W4386326323 hasConceptScore W4386326323C2776694085 @default.
• W4386326323 hasConceptScore W4386326323C2777364431 @default.
• W4386326323 hasConceptScore W4386326323C2779900020 @default.
• W4386326323 hasConceptScore W4386326323C3019080777 @default.
• W4386326323 hasConceptScore W4386326323C515549039 @default.
• W4386326323 hasConceptScore W4386326323C64332521 @default.
• W4386326323 hasConceptScore W4386326323C71924100 @default.
• W4386326323 hasConceptScore W4386326323C86803240 @default.
• W4386326323 hasLocation W43863263231 @default.
• W4386326323 hasLocation W43863263232 @default.
• W4386326323 hasOpenAccess W4386326323 @default.
• W4386326323 hasPrimaryLocation W43863263231 @default.
• W4386326323 hasRelatedWork W2030907617 @default.
• W4386326323 hasRelatedWork W2076400280 @default.
• W4386326323 hasRelatedWork W2145952979 @default.

• next